The effectiveness of intradermal injection and topical tranexamic acid in melasma
Keywords:Tranexamic acid, melasma, hyperpigmentation, injection tranexamic acid, effectiveness
AbstractBackground: Melasma is a hyperpigmentation disorder caused by the hyperactivity of epidermal melanocytes in the facial area that is very common in Asian races. Previous studies revealed that patients with melasma want a short duration of therapy and inexpensive costs. This study elucidate the effectiveness of intradermal injection compared with topical tranexamic acid (TA) in melasma. Methods: The research subjects were divided into 2 groups accordingly. The test groups received intradermal tranexamic acid injections every four weeks for eight weeks, while the control group received topical tranexamic acid applied by compressed dressing every two weeks for eight weeks. MASI score and melanin index were measured at the beginning and end of the study. Results: 18 patients (56%) received an intradermal tranexamic acid injection, and 14 patients (44%) received topical tranexamic acid. There was a decrease in the mean value of the melanin index and MASI score in the topical TA group before and after the sequential treatment (p <0.05). There was a decrease in the mean value of melanin index and MASI score in the topical TA group before and after the sequential treatment (p <0.05). There were significant mean differences in melanin index and MASI score before and after treatment between the topical and injection TA groups (p <0.05). Conclusions: TA injection is more effective in reducing MASI scores and melanin index compared to topical TA in melasma, with longer treatment intervals and lower cost-effectiveness.
Colferai MMT, Miquelin GM, Steiner D. Evaluation of oral tranexamic acid in the treatment of melasma. J Cosmet Dermatol. 2019 Oct 9;18(5):1495–501.
Taraz M, Niknam S, Ehsani AH. Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies. Dermatol Ther. 2017 May;30(3):e12465.
Yalamanchili R, Shastry V, Betkerur J. Clinico-epidemiological study and quality of life assessment in melasma. Indian J Dermatol. 2015;60(5):519.
Kim H, Moon S, Cho S, Lee J, Kim H. Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review. Acta Derm Venereol. 2017;97(7):776–81.
Bala HR, Lee S, Wong C, Pandya AG, Rodrigues M. Oral Tranexamic Acid for the Treatment of Melasma: A Review. Dermatologic Surg. 2018 Jun;44(6):814–25.
Steiner, Denise; Feola, Vamila; Bialeski, Nediana; Silva F. Study evaluating the efficacy of topical and injected tranexamic acid in treatment of melasma. Surg Cosmet Dermatology. 2009;14:174–7.
Kanechorn Na Ayuthaya P, Niumphradit N, Manosroi A, Nakakes A. Topical 5% tranexamic acid for the treatment of melasma in Asians: A double-blind randomized controlled clinical trial. J Cosmet Laser Ther. 2012 Jun 16;14(3):150–4.
Banihashemi M, Zabolinejad N, Jaafari MR, Salehi M, Jabari A. Comparison of therapeutic effects of liposomal Tranexamic Acid and conventional Hydroquinone on melasma. J Cosmet Dermatol. 2015 Sep;14(3):174–7.
Kim SJ, Park J-Y, Shibata T, Fujiwara R, Kang HY. Efficacy and possible mechanisms of topical tranexamic acid in melasma. Clin Exp Dermatol. 2016 Jul;41(5):480–5.
Miyar A, Habibi I, Ebrahimi A, Mansourpour D, Mokarizadeh A, Rajabi A, et al. Predictive and prognostic value of TLR9 and NFKBIA gene expression as potential biomarkers for human glioma diagnosis. J Neurol Sci. 2016;368:314–7.
Chung JY, Lee JH, Lee JH. Topical tranexamic acid as an adjuvant treatment in melasma: Side-by-side comparison clinical study. J Dermatolog Treat. 2016 Jul 3;27(4):373–7.
Shankar K, Godse K, Aurangabadkar S, Lahiri K, Mysore V, Ganjoo A, et al. Evidence-Based Treatment for Melasma: Expert Opinion and a Review. Dermatol Ther (Heidelb). 2014 Dec 1;4(2):165–86.
Mahajan VK, Patil A, Blicharz L, Kassir M, Konnikov N, Gold MH, et al. Medical therapies for melasma. J Cosmet Dermatol. 2022 Sep;21(9):3707–28.
LEE JH, PARK JG, LIM SH, KIM JY, AHN KY, KIM M-Y, et al. Localized Intradermal Microinjection of Tranexamic Acid for Treatment of Melasma in Asian Patients: A Preliminary Clinical Trial. Dermatologic Surg. 2006 May;32(5):626–31.
Budamakuntla L, Loganathan E, Suresh D, Shanmugam S, Dongare A, Prabhu N, et al. A randomised, open-label, comparative study of tranexamic acid microinjections and tranexamic acid with microneedling in patients with melasma. J Cutan Aesthet Surg. 2013;6(3):139.
Elfar NN. Efficacy of Intradermal Injection of Tranexamic Acid, Topical Silymarin and Glycolic Acid Peeling in Treatment of Melasma: A Comparative Study. J Clin Exp Dermatol Res. 2015;06(03).
Saki N, Darayesh M, Heiran A. Comparing the efficacy of topical hydroquinone 2% versus intradermal tranexamic acid microinjections in treating melasma: a split-face controlled trial. J Dermatolog Treat. 2018 May 19;29(4):405–10.
Ebrahimi B, Naeini FF. Topical tranexamic acid as a promising treatment for melasma. J Res Med Sci. 2014 Aug;19(8):753–7.
Janney MS, Subramaniyan R, Dabas R, Lal S, Das NM, Godara SK. A Randomized Controlled Study Comparing the Efficacy of Topical 5% Tranexamic Acid Solution versus 3% Hydroquinone Cream in Melasma. J Cutan Aesthet Surg. 2019;12(1):63–7.